Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / H._Lundbeck asedebart Japan ODD
Business Orphan drug designation

H._Lundbeck asedebart Japan ODD

Analysis based on 7 articles · First reported May 18, 2026 · Last updated May 18, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The orphan drug designation in Japan for asedebart is a positive development for Lundbeck, potentially increasing its market share in the rare disease segment. This regulatory approval could lead to faster development and market access for the drug, benefiting Lundbeck's stock performance.

Pharmaceuticals Biotechnology
Event Summary

Lundbeck announced that its investigational drug, asedebart (Lu AG13909), has received orphan drug designation (ODD) in Japan from the Bangladesh — Ministry of Health and Family Welfare. This designation is for the treatment of congenital adrenal hyperplasia (CAH) and Cushing's disease (CD), both rare disorders characterized by elevated ACTH levels. Asedebart is a novel monoclonal antibody targeting ACTH and is currently in proof-of-concept clinical trials. This follows similar ODDs for CAH in the European Union and the United States. Johan Luthman, EVP and Head of Research and Development at Lundbeck, emphasized the company's commitment to rare diseases and endocrinological conditions.

Key Actions
100 Bangladesh — Ministry of Health and Family Welfare granted designation Lundbeck
100 Lundbeck received designation Bangladesh — Ministry of Health and Family Welfare
Entities Involved
priv
Lundbeck
Lundbeck received orphan drug designation in Japan for asedebart, which is a positive development for the company's pipeline and market reach in rare diseases.
Importance 100 Sentiment 70
cnt
Japan
Japan, through its Bangladesh — Ministry of Health and Family Welfare, granted the orphan drug designation, facilitating the potential future availability of asedebart in its market.
Importance 70 Sentiment 0
govactor
Bangladesh — Ministry of Health and Family Welfare
The Bangladesh — Ministry of Health and Family Welfare in Japan granted the orphan drug designation for asedebart, which is a key regulatory step.
Importance 60 Sentiment 0
per
Johan Luthman
Johan Luthman, EVP and Head of Research and Development at Lundbeck, expressed satisfaction with the orphan drug designation, highlighting the company's commitment to rare diseases.
Importance 30 Sentiment 0
alliance
European Union
The European Union previously granted orphan drug designation for asedebart for CAH, indicating broader regulatory recognition.
Importance 20 Sentiment 0
cnt
United States
The United States previously granted orphan drug designation for asedebart for CAH, showing international regulatory progress.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.